Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
NCT ID: NCT06810050
Last Updated: 2025-02-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
180 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-12-18
Study Completion Date
2025-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are:
Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis.
Participants will:
Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks.
Keep a diary of when they use the product and complete a form about their symptoms including itching.
Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis.
Participants will:
Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks.
Keep a diary of when they use the product and complete a form about their symptoms including itching.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
NCT06923228
Atopic Dermatitis (AD)
NOT_YET_RECRUITING
PHASE2
Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
NCT05487963
Atopic Dermatitis
COMPLETED
PHASE1/PHASE2
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
NCT02001181
Dermatitis, Atopic
COMPLETED
PHASE2
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
NCT02118766
Dermatitis, Atopic
COMPLETED
PHASE3
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
NCT02118792
Dermatitis, Atopic
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objectives of this study:
* To evaluate the safety and tolerability of CGB-500 topical ointment with 0.5% and 1% tofacitinib for the treatment of atopic dermatitis (AD)
* To evaluate the effectiveness of CGB-500 topical ointment with 0.5% and 1% tofacitinib for the treatment of AD
Key trial design:
Intervention Model: Parallel-group Population Type: Pediatric and adult participants Control: Vehicle (without tofacitinib) Population Diagnosis or Condition: Atopic dermatitis Active Comparator: N/A Population Age: ≥ 12 years Trial Intervention Assignment Method: Randomization Site Distribution: US multicenter Number of Arms: 3 Blinding: participants and investigational staff (sponsor, investigator, and evaluators) Number of Participants: 160 to 180
Arms and Duration:
Total duration of trial intervention for each participant: 8 weeks Total duration of trial participation for each participant: Approximately 10 weeks, 2 weeks of screening and 8 weeks of treatment
Arms and Duration Description:
All participants will undergo approximately 2 weeks (Day -15 to Day -1) of screening and 8 weeks of treatment and will be randomized in a 1:1:1 ratio to the following treatment arms. The goal is to randomize 60 participants with a minimum of 48 participants in each of the arms.
* CGB-500 Topical Ointment with 0.5% Tofacitinib BID
* CGB-500 Topical Ointment with 1% Tofacitinib BID
* Vehicle for CGB-500 Topical Ointment BID
* To evaluate the safety and tolerability of CGB-500 topical ointment with 0.5% and 1% tofacitinib for the treatment of atopic dermatitis (AD)
* To evaluate the effectiveness of CGB-500 topical ointment with 0.5% and 1% tofacitinib for the treatment of AD
Key trial design:
Intervention Model: Parallel-group Population Type: Pediatric and adult participants Control: Vehicle (without tofacitinib) Population Diagnosis or Condition: Atopic dermatitis Active Comparator: N/A Population Age: ≥ 12 years Trial Intervention Assignment Method: Randomization Site Distribution: US multicenter Number of Arms: 3 Blinding: participants and investigational staff (sponsor, investigator, and evaluators) Number of Participants: 160 to 180
Arms and Duration:
Total duration of trial intervention for each participant: 8 weeks Total duration of trial participation for each participant: Approximately 10 weeks, 2 weeks of screening and 8 weeks of treatment
Arms and Duration Description:
All participants will undergo approximately 2 weeks (Day -15 to Day -1) of screening and 8 weeks of treatment and will be randomized in a 1:1:1 ratio to the following treatment arms. The goal is to randomize 60 participants with a minimum of 48 participants in each of the arms.
* CGB-500 Topical Ointment with 0.5% Tofacitinib BID
* CGB-500 Topical Ointment with 1% Tofacitinib BID
* Vehicle for CGB-500 Topical Ointment BID
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Atopic Dermatitis (AD)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CGB 500 ointment with 0.5% tofacitinib
Group Type
EXPERIMENTAL
CGB-500 with 0.5% tofacitinib
Intervention Type
DRUG
CGB-500 is a proprietary ointment formulation
CGB 500 ointment with 1% tofacitinib
Group Type
EXPERIMENTAL
CGB-500 Ointment with 1% tofacitinib
Intervention Type
DRUG
CGB-500 is a proprietary ointment formulation
vehicle ointment
Group Type
PLACEBO_COMPARATOR
Vehicle (placebo)
Intervention Type
DRUG
placebo ointment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CGB-500 with 0.5% tofacitinib
CGB-500 is a proprietary ointment formulation
Intervention Type
DRUG
CGB-500 Ointment with 1% tofacitinib
CGB-500 is a proprietary ointment formulation
Intervention Type
DRUG
Vehicle (placebo)
placebo ointment
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
To be eligible to participate in this trial, an individual must meet all of the following criteria:
1. Outpatient, male or female of any race, 12 years of age or older. Females of childbearing potential (FOBCP) must have a negative urine pregnancy test at Screening and Baseline and practice a reliable method of contraception throughout the trial.
2. Have a clinical diagnosis of atopic dermatitis (AD) for at least 12 months prior to Baseline that has been clinically stable disease for ≥ 3 months at the time of the screening visit and prior to dose administration and is confirmed to be AD according to the criteria of Hanifin and Rajka.
3. Have an IGA (Investigator's Global Assessment) score of 2, 3, or 4 at Screening and Baseline.
4. Have AD lesions/symptoms covering at least 1% but less than 10% of total BSA (excluding scalp, genitalia, palms, and soles) at Screening and Baseline.
5. Have at least 1 "target lesion" that measures approximately 10 cm2 or more at Screening and Baseline. Lesion must be representative of the participant's disease state and not be located on the scalp, genitalia, palms, or soles.
6. In general, good health as determined by medical history and physical examination at the time of screening (investigator discretion).
7. Have peak pruritus numeric rating scale (PPNRS) score of ≥ 4 on the scale 0 to 10 at Screening and Baseline.
8. Be able to follow trial instructions and likely to complete all required visits.
9. Sign the institutional review board (IRB)-approved informed consent form (ICF, which includes HIPAA) and assent prior to any trial-related procedures being performed.
1. Outpatient, male or female of any race, 12 years of age or older. Females of childbearing potential (FOBCP) must have a negative urine pregnancy test at Screening and Baseline and practice a reliable method of contraception throughout the trial.
2. Have a clinical diagnosis of atopic dermatitis (AD) for at least 12 months prior to Baseline that has been clinically stable disease for ≥ 3 months at the time of the screening visit and prior to dose administration and is confirmed to be AD according to the criteria of Hanifin and Rajka.
3. Have an IGA (Investigator's Global Assessment) score of 2, 3, or 4 at Screening and Baseline.
4. Have AD lesions/symptoms covering at least 1% but less than 10% of total BSA (excluding scalp, genitalia, palms, and soles) at Screening and Baseline.
5. Have at least 1 "target lesion" that measures approximately 10 cm2 or more at Screening and Baseline. Lesion must be representative of the participant's disease state and not be located on the scalp, genitalia, palms, or soles.
6. In general, good health as determined by medical history and physical examination at the time of screening (investigator discretion).
7. Have peak pruritus numeric rating scale (PPNRS) score of ≥ 4 on the scale 0 to 10 at Screening and Baseline.
8. Be able to follow trial instructions and likely to complete all required visits.
9. Sign the institutional review board (IRB)-approved informed consent form (ICF, which includes HIPAA) and assent prior to any trial-related procedures being performed.
Exclusion Criteria
An individual who meets any of the following criteria will be excluded from participation in this trial:
1. Females who are pregnant, breastfeeding, intending to be pregnant during the trial, or who do not agree to use an acceptable form of birth control during the trial if of childbearing potential .
2. Immunocompromised individuals as adjudicated by the principal investigator (PI) based on review of medical history.
3. Known hypersensitivity or previous allergic reaction to any constituent of the IP (e.g., tofacitinib or Janus kinase (JAK) inhibitors, essential oils, choline, phosphatidylcholine, glycerol, propylene glycol, polyethylene glycol).
4. Has clinically significant safety labs (hematology, chemistry, and urinalysis) at the Screening visit that, in the opinion of the investigator, would preclude participation in the study or affect proper assessment of the study endpoints
5. Skin infections (e.g., bacterial, fungal or viral) that can interfere with reliable AD assessments.
6. Basal cell carcinoma within 6 months prior to Baseline.
7. History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, or ichthyosis or presence of Netherton's Syndrome, immunological deficiencies or diseases, HIV, uncontrolled diabetes, malignancy, or serious active or recurrent infection.
8. Known hepatic impairment or disorder and/or ALT and AST \>3X ULN at Screening.
9. Has unstable and impaired renal function with an estimated glomerular filtration rate (eGFR) \<60 mL/min using Cockcroft-Gault (C-G) equation (eGFR between 60 to \<90 mL/minute or higher is acceptable).
10. Use of moderate to strong CYP3A4 and CYP3A5 inhibitors (e.g. ritonavir, clarithromycin, itraconazole, erythromycin, fluconazole, verapamil, ketoconazole, nefazodone, nelfinavir, diltiazem, ciprofloxacin, grapefruit juice) within 4 weeks prior to Baseline.
11. Participants who have previously failed or had an inadequate response to oral, systemic or topical JAK inhibitors, including in a trial or under a prescription for atopic dermatitis (e.g., ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).
12. Participants who had an adequate response to JAK inhibitors will be excluded if the following are met:
1. Use within 2 weeks prior to Baseline of topical JAK inhibitors.
2. Use within 4 weeks prior to Baseline of systemic JAK inhibitors.
13. Use within 14 days prior to Baseline of: 1) systemic antibiotics, 2) calcipotriene or 3) retinoids.
14. Use within 7 days on the treatment area(s) prior to Baseline of: 1) topical antihistamines, 2) topical antibiotics, 3) topical corticosteroids or 4) other topical drug products.
15. Use of the following treatments prior to Baseline:
1. For 5 half-lives or 12 weeks (whichever is longer) - biologic agents (e.g., dupilumab).
2. For 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogs, cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (e.g., mycophenolate or tacrolimus).
3. For 2 weeks - UVA/UVB therapy, PUVA (psoralen plus ultraviolet) therapy, tanning booths, or non-prescription UV light sources.
4. For 2 weeks - immunizations and sedating antihistamines unless on long-term stable regimen (nonsedating antihistamines are permitted).
5. For 2 weeks - use of other topical treatments for atopic dermatitis (other than bland emollients). Diluted sodium hypochlorite "bleach" baths are allowed if they do not exceed 2 baths per week and their frequency remains the same throughout the trial.
16. Uncontrolled systemic disease.
17. Any serious illness or condition(s) that, in the opinion of the PI, would interfere with full participation in the trial, including administration of IP and attending required trial visits; pose a significant risk to the participant; or interfere with interpretation of trial data.
18. Foreseen unprotected and intense/excessive UV exposure during the trial.
19. Scheduled or planned surgical procedures during the trial.
20. Unable or unwilling to comply with any of the trial requirements.
21. Medical or psychiatric conditions, or a personal situation, that may increase the risk associated with trial participation or may interfere with interpretation of trial results or participant compliance and, in the opinion of the PI, makes the participant inappropriate for trial entry.
22. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
23. Employees of the research center or Investigator.
24. Family of members of employees of the research center or Investigator.
25. Participants (e.g. siblings, spouses, relatives, roommates) residing in the same household cannot be enrolled at the same time.
\-
1. Females who are pregnant, breastfeeding, intending to be pregnant during the trial, or who do not agree to use an acceptable form of birth control during the trial if of childbearing potential .
2. Immunocompromised individuals as adjudicated by the principal investigator (PI) based on review of medical history.
3. Known hypersensitivity or previous allergic reaction to any constituent of the IP (e.g., tofacitinib or Janus kinase (JAK) inhibitors, essential oils, choline, phosphatidylcholine, glycerol, propylene glycol, polyethylene glycol).
4. Has clinically significant safety labs (hematology, chemistry, and urinalysis) at the Screening visit that, in the opinion of the investigator, would preclude participation in the study or affect proper assessment of the study endpoints
5. Skin infections (e.g., bacterial, fungal or viral) that can interfere with reliable AD assessments.
6. Basal cell carcinoma within 6 months prior to Baseline.
7. History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, or ichthyosis or presence of Netherton's Syndrome, immunological deficiencies or diseases, HIV, uncontrolled diabetes, malignancy, or serious active or recurrent infection.
8. Known hepatic impairment or disorder and/or ALT and AST \>3X ULN at Screening.
9. Has unstable and impaired renal function with an estimated glomerular filtration rate (eGFR) \<60 mL/min using Cockcroft-Gault (C-G) equation (eGFR between 60 to \<90 mL/minute or higher is acceptable).
10. Use of moderate to strong CYP3A4 and CYP3A5 inhibitors (e.g. ritonavir, clarithromycin, itraconazole, erythromycin, fluconazole, verapamil, ketoconazole, nefazodone, nelfinavir, diltiazem, ciprofloxacin, grapefruit juice) within 4 weeks prior to Baseline.
11. Participants who have previously failed or had an inadequate response to oral, systemic or topical JAK inhibitors, including in a trial or under a prescription for atopic dermatitis (e.g., ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).
12. Participants who had an adequate response to JAK inhibitors will be excluded if the following are met:
1. Use within 2 weeks prior to Baseline of topical JAK inhibitors.
2. Use within 4 weeks prior to Baseline of systemic JAK inhibitors.
13. Use within 14 days prior to Baseline of: 1) systemic antibiotics, 2) calcipotriene or 3) retinoids.
14. Use within 7 days on the treatment area(s) prior to Baseline of: 1) topical antihistamines, 2) topical antibiotics, 3) topical corticosteroids or 4) other topical drug products.
15. Use of the following treatments prior to Baseline:
1. For 5 half-lives or 12 weeks (whichever is longer) - biologic agents (e.g., dupilumab).
2. For 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogs, cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (e.g., mycophenolate or tacrolimus).
3. For 2 weeks - UVA/UVB therapy, PUVA (psoralen plus ultraviolet) therapy, tanning booths, or non-prescription UV light sources.
4. For 2 weeks - immunizations and sedating antihistamines unless on long-term stable regimen (nonsedating antihistamines are permitted).
5. For 2 weeks - use of other topical treatments for atopic dermatitis (other than bland emollients). Diluted sodium hypochlorite "bleach" baths are allowed if they do not exceed 2 baths per week and their frequency remains the same throughout the trial.
16. Uncontrolled systemic disease.
17. Any serious illness or condition(s) that, in the opinion of the PI, would interfere with full participation in the trial, including administration of IP and attending required trial visits; pose a significant risk to the participant; or interfere with interpretation of trial data.
18. Foreseen unprotected and intense/excessive UV exposure during the trial.
19. Scheduled or planned surgical procedures during the trial.
20. Unable or unwilling to comply with any of the trial requirements.
21. Medical or psychiatric conditions, or a personal situation, that may increase the risk associated with trial participation or may interfere with interpretation of trial results or participant compliance and, in the opinion of the PI, makes the participant inappropriate for trial entry.
22. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
23. Employees of the research center or Investigator.
24. Family of members of employees of the research center or Investigator.
25. Participants (e.g. siblings, spouses, relatives, roommates) residing in the same household cannot be enrolled at the same time.
\-
Minimum Eligible Age
12 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CAGE Bio Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Dermatology Clinical Research Inc.
Fremont, California, United States
Site Status
RECRUITING
Ablon Skin Institute and Research Center
Manhattan Beach, California, United States
Site Status
RECRUITING
TCR Medical Corporation
San Diego, California, United States
Site Status
RECRUITING
Syrentis Clinical Research
Santa Ana, California, United States
Site Status
RECRUITING
USA and International Research Inc.
Doral, Florida, United States
Site Status
RECRUITING
FXM Clinical Research
Fort Lauderdale, Florida, United States
Site Status
RECRUITING
Driven Research
Gables, Florida, United States
Site Status
RECRUITING
FXM Clinical Research Miami, LLC
Miami, Florida, United States
Site Status
RECRUITING
FXM Clinical Research Miramar, LLC
Miramar, Florida, United States
Site Status
RECRUITING
Cordova Research Institute
Sweetwater, Florida, United States
Site Status
RECRUITING
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, United States
Site Status
RECRUITING
Metro Boston Clinical Partners
Brighton, Massachusetts, United States
Site Status
RECRUITING
J&S Studies, Inc.
New Brighton, Minnesota, United States
Site Status
RECRUITING
JDR Dermatology Research
Las Vegas, Nevada, United States
Site Status
RECRUITING
Tennessee Clinical Research Center
Nashville, Tennessee, United States
Site Status
RECRUITING
DermResearch
Austin, Texas, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Neal Bhatia, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CGB-500-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
NCT04313400
COMPLETED
PHASE1/PHASE2
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
NCT02087943
COMPLETED
PHASE2
A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis
NCT02068352
COMPLETED
PHASE2
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
NCT03826901
COMPLETED
PHASE1
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
NCT01552629
COMPLETED
PHASE2
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05999799
TERMINATED
PHASE2
A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis
NCT01808157
COMPLETED
PHASE2
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
NCT02564055
COMPLETED
PHASE2
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
NCT06504160
RECRUITING
PHASE1/PHASE2
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
NCT01652885
COMPLETED
PHASE1/PHASE2
Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis
NCT01301508
COMPLETED
PHASE2
Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
NCT02925793
COMPLETED
PHASE2
A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis
NCT00703573
COMPLETED
PHASE2
Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis
NCT00919763
COMPLETED
PHASE2
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
NCT05935085
TERMINATED
PHASE2
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
NCT04975438
COMPLETED
PHASE1
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
NCT01702181
COMPLETED
PHASE1
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
NCT03233529
COMPLETED
PHASE2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961
RECRUITING
PHASE2
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577
RECRUITING
PHASE2
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
NCT01139450
COMPLETED
PHASE3
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333
COMPLETED
PHASE1/PHASE2
Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis
NCT03415282
UNKNOWN
PHASE1
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
NCT04936113
TERMINATED
PHASE2
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948
ACTIVE_NOT_RECRUITING
PHASE2